ArticleBMC geriatrics2026
Treatment patterns, and outcomes in elderly patients with metastatic non-small cell lung cancer: a real-world analysis from a single center in China.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective cohort study aims to describe the treatment patterns and evaluate survival outcomes in patients aged 70 years or older with metastatic non-small cell lung cancer (mNSCLC), and to identify independent prognostic factors for overall survival (OS).
methodsWe retrospectively reviewed medical records of 298 patients aged ≥70 years with mNSCLC diagnosed between June 2021 and December 2024. Patients were categorized into an active anti-tumor therapy (ATT) group and a best supportive care (BSC) group for descriptive purposes. Key clinical data, including molecular biomarker status (EGFR, ALK, PD-L1) and Geriatric Nutritional Risk Index (GNRI), were collected for a subset of patients. A multivariate Cox proportional-hazards model was used to identify independent prognostic factors for OS across the entire cohort.
resultsOf the 298 patients, 93 (31.2%) received ATT and 205 (68.8%) received BSC. The decision for ATT was significantly associated with better baseline ECOG performance status (ECOG-PS) and fewer comorbidities, indicating profound selection bias. The median OS was 18.0 months in the ATT group and 6.0 months in the BSC group. This difference is descriptive and cannot be interpreted as a treatment effect due to the baseline imbalances. Within the ATT group, treatment modalities included chemotherapy (n = 54), targeted therapy (n = 11), and combination therapy (n = 28). In the multivariate analysis of the entire cohort, better ECOG PS (0–1 vs. 4: HR = 0.28, P < 0.01), fewer comorbidities (0 vs. ≥3: HR = 0.17, P < 0.001), higher GNRI (≥ 98 vs. <92: HR = 0.55, P = 0.02), and adenocarcinoma histology (vs. non-adenocarcinoma: HR = 0.68, P = 0.04) were independent predictors of longer OS.
conclusionIn this real-world cohort of elderly mNSCLC patients, treatment selection was heavily influenced by baseline health status. Independent prognostic factors for longer survival were better performance status, lower comorbidity burden, better nutritional status (higher GNRI), and adenocarcinoma histology. These findings underscore the importance of comprehensive geriatric and nutritional assessment in this population and highlight the need for prospective trials to guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.